Kamada Announces US Proof-of-Concept Study with Glassia® for Graft-Versus ... Business Wire (press release) The POC study is a Phase 1/2 study of 24 patients with steroid-resistant GVHD following allogeneic bone-marrow stem cell transplant who will receive six to ten doses of intravenously delivered Glassia to determine safety, optimal dose and clinical ... |
